ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

NEPH vs DRIO // REVENUE GROWTH (YOY)

Nephros Inc. (NASDAQ) VS. DarioHealth Corp. (NASDAQ) • 15-METRIC TALLY: NEPH 7 — DRIO 0
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NEPH VS. DRIO) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC NEPH DRIO SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 61.90% 56.60% +5.30 NEPH /gross-margins <GO>
Return on Invested Capital (ROIC) 18.90% -35.00% +53.90 NEPH /roic <GO>
EV/EBITDA & P/E Valuation 26.3x — — TIE /valuation <GO>
Free Cash Flow Yield 4.50% — — TIE /fcf-yield <GO>
Operating Margin 6.10% -60.00% +66.10 NEPH /operating-margins <GO>
Net Profit Margin 6.40% -60.00% +66.40 NEPH /net-margins <GO>
Revenue Growth (YoY) ACTIVE 32.70% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 8/9 5/9 +3.00 NEPH /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 40.5 29.8 +10.70 NEPH /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 25.0x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $35.5M $32.4M $3.1M NEPH /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR NEPH REV DRIO REV NEPH GROSS % DRIO GROSS % NEPH FCF DRIO FCF
FY 2025 $18.8M $22.4M 61.9% 56.6% $1.6M -$26.1M
FY 2024 $14.2M $27.0M 61.6% 49.1% -$547.0K -$38.7M
FY 2023 $14.2M $0 — — $827.0K -$30.4M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NEPH // BETA —
DRIO // BETA —